Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.060 -0.320 (-3.82%)
Streaming Delayed Price Updated: 9:53 AM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,350,747
Open 7.820
Bid (Size) 8.050 (800)
Ask (Size) 8.070 (1,100)
Prev. Close 8.380
Today's Range 7.660 - 8.080
52wk Range 1.830 - 12.43
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline is May 26, 2026 to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox
NEW YORK, NY - May 7, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) on... 
Via TheNewswire.com
Topics Lawsuit

Performance

YTD
+299.0%
+299.0%
1 Month
+13.8%
+13.8%
3 Month
+37.1%
+37.1%
6 Month
+274.9%
+274.9%
1 Year
+301.0%
+301.0%

More News

Read More
News headline image
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ImmunityBio Inc (NASDAQ:IBRX) Q1 Revenue Beat Overshadowed by Wider Losses and Stock Decline ↗
Via Chartmill
News headline image
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
From SkyMedia, LLC
Via GlobeNewswire
News headline image
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
From SkyMedia, LLC
Via GlobeNewswire
News headline image
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.
From Robbins LLP
Via Business Wire
News headline image
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 8.060
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 05/07/26 09:53 AM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 3.15B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.